Abstract：Objective The objective of our study was to conduct meta-analyses that examined the association between H7N9-infected case-fatality risk（CFR）and underlying medical conditions（UMCs）by adjusting some potential factors variables. Methods The articles of observational studies and randomized controlled clinical trials（RCT）on the association between UMCs and the CFR of H7N9-infected patients were collected and selected according to inclusion and exclusion criteria. Meta-analysis was performed to calculate odds ratio（OR）or adjusted OR（AOR）and 95% confidence interval（CI）to assess the association between H7N9-infected CFR and UMCs. Results Among 1 934 screened articles，we identified 14 articles reporting the CFR of H7N9-infected patients based on UMCs data. The pooled summary estimates from these studies indicated that UMCs significantly increased the risk of death in H7N9 patients （OR=2.20，95%CI：1.76-2.76）. Subgroup analyses showed chronic respiratory diseases （CRD，OR=4.43，95%CI：1.73-11.31），immuno-suppressive disorders（ISD，OR=4.65，95% CI：1.48-44.70），and two UMCs and above（OR=2.13，95% CI：1.26-5.97） were significantly associated with H7N9-infected CFR； while 60 years old and above （AOR=4.83，95%CI：1.29-18.09），male（AOR=2.35，95%CI：1.03-5.39），time intervals to oseltamivir treatment（over 5 days）（AOR=5.74，95%CI：1.15-28.66）and hospitalization（over 8 days）（AOR=2.72，95%CI：1.20-6.15），and initially bilateral lungs infection（AOR=7.95，95%CI：1.56-40.41）of UMCs patients who died from H7N9 infection are much greater compared with non-UMCs. Stratification analyses confirmed statistically significant increasing effects of CFR were observed in 60 years old and above（AOR=2.20，95%CI：1.12-4.30），time intervals to oseltamivir treatment（over 5 days）（AOR=3.19，95%CI：1.56-6.53），and initially bilateral lungs infection（AOR=3.48， 95%CI：1.74-6.95）compared with 0-59 years old，time intervals to oseltamivir treatment（5 days and below），and initially single lung infection respectively in H7N9-infected patients with UMCs. Conclusions We find that only CRD，ISD，and two UMCs and above are associated with increased risk of death in H7N9-infected patients. We also suggest that a high CFR is associated with 60 years old and above，delayed antiviral treatment，and initially bilateral lungs infection in H7N9-infected patients with UMCs.
杨洛贤, 程庆林, 张琼, 谢立. 慢性基础疾病与人感染H7N9禽流感病死风险校正关联性的Meta分析[J]. 预防医学, 2018, 30(6): 557-564,569.
YANG Luo-xian, CHENG Qing-lin, ZHANG Qiong, XIE Li. Association between underlying medical conditions and fatality risk in H7N9-infected patients: a meta-analysis. Preventive Medicine, 2018, 30(6): 557-564,569.
[1] ZHANG Y，LIU J，YU L，et al. Prevalence and characteristics of hypoxic hepatitis in the largest single-centre cohort of avian influenza A（H7N9）virus-infected patients with severe liver impairment in the intensive care unit[J] . Emerg Microbes Infect，2016，5：el. [2] FENG F，JIANG Y，YUAN M，et al. Association of radiologic findings with mortality in patients with avian influenza H7N9 pneumonia[J] . PLoS ONE，2014，9（4）：e93885. [3] WANG C，YU H，HORBY P W，et al. Comparison of patients hospitalized with influenza A subtypes H7N9，H5N1，and 2009 pandemic H1N1[J] . Clin Infect Dis，2014，58（8）：1095- 1103. [4] LU S，ZHENG Y，LI T，et al. Clinical Findings for Early Human Cases of Influenza A（H7N9） Virus Infection，Shanghai，China[J] . Emerging Infectious Diseases，2013，19（7）：1142-1146. [5] Oxford centre for evidence-based medicine. Critical Appraisal Skills Programme（CASP）[EB/OL] .（2017-06-04）（2017-10-12] . http：//www.casp-uk.net/. [6] JI H，GU Q，CHEN L L，et al. Epidemiological and clinical characteristics and risk factors for death of patients with avian influenza A H7N9 virus infection from Jiangsu Province，Eastern China[J] . PLoS ONE，2014，9（3）：e89581. [7] VIRLOGEUX V，YANG J，FANG V J，et al. Association between the severity of influenza A（H7N9）virus infections and length of the incubation period[J] . PLoS ONE，2016，11（2）：e0148506. [8] LIU S，SUN J，CAI J，et al. Epidemiological，clinical and viral characteristics of fatal cases of human avian influenza A （H7N9） virus in Zhejiang Province，China[J] . J Infect，2013，67（6）：595-605. [9] LIU X，ZHANG Y，XU X，et al. Evaluation of plasma exchange and continuous veno-venous hemofiltration for the treatment of severe avian influenza A （H7N9）：a cohort study[J] . Ther Apher Dial，2015，19（2）：178-184. [10] ZHANG A，HUANG Y，TIAN D，et al. Kinetics of serological responses in influenza A（H7N9）-infected patients correlate with clinical outcome in China，2013[J] . European communicable disease bulletin，2013，18（50）：20657. [11] CHENG Q L，DING H，SUN Z，et al. Retrospective study of risk factors for mortality in human avian influenza A（H7N9）cases in Zhejiang Province，China，March 2013 to June 2014[J] . Int J Infect Dis，2015，39：95-101. [12] 谢立，程庆林，丁华，等. 杭州市人感染 H7N9禽流行性感冒死亡危险因素分析[J] . 中华传染病杂志，2014，32（11）：683- 687. [13] 柴程良，陈恩富，陈直平，等. 浙江省6例人感染H7N9禽流感确诊病例的临床与流行病学特征分析[J] . 中华流行病学杂志，2013，34（5）：443-445. [14] WU Z Q，ZHANG Y，ZHAO N，et al. Comparative epidemiology of human fatal infections with novel，high（H5N6 and H5N1）and low（H7N9 and H9N2）pathogenicity avian influenza a viruses[J] . International Journal of Environmental Research and Public Health，2017，14（12）：263. [15] WANG H，XIAO X，LU J，et al. Factors associated with clinical outcome in 25 patients with avian influenza A（H7N9）infection in Guangzhou，China[J] . BMC Infect Dis，2016，16（1）：534. [16] CHEN Y，LI X，TIAN L，et al. Dynamic behavior of lymphocyte subgroups correlates with clinical outcomes in human H7N9 infection[J] . J Infect，2014，69（4）：358-365. [17] PEBODY R G，MCLEAN E，ZHAO H，et al. Pandemic Influenza A（H1N1）2009 and mortality in the United Kingdom：risk factors for death，April 2009 to March 2010[J] . Euro surveillance，2010，15（20）：pii/19564- pii/19564. [18] RIBEIRO A F，PELLINI A C，KITAGAWA B Y，et al. Risk factors for death from Influenza A（H1N1）pdm09，State of S?o Paulo，Brazil，2009[J] . PLoS ONE，2015，10（3）：e0118772. [19] HENNESSY T W，BRUDEN D，CASTRODALE L，et al. A case-control study of risk factors for death from 2009 pandemic influenza A（H1N1）：is American Indian racial status an independent risk factor?[J] . Epidemiology and Infection，2015（2）：315-324. [20] GAO H N，LU H Z，CAO B，et al. Clinical findings in 111 cases of influenza A（H7N9）virus infection[J] . N Engl J Med，2013，368（24）：2277-2285. [21] GUAN Y，FAROOQUI A，ZHU H，et al. H7N9 Incident，immune status，the elderly and a warning of an influenza pandemic[J] . J Infect Dev Ctries，2013，7（4）：302-307. [22] BERMEJO-MARTIN J F，ALMANSA R，ORTIZ DE LEJARAZU R. Weakened immunity in aged hosts with comorbidities as a risk factor for the emergence of influenza A H7N9 mutants[J] . J Infect Dev Ctries，2013，7（6）：497-498. [23] ZHOU Y，WANG C，YAO W，et al. COPD in Chinese nonsmokers[J] . Eur Respir J，2009，33（3）：509-518. [24] KAISER L，WAT C，MILLS T，et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations[J] . Arch Intern Med，2003，163（14）：1667-1672. [25] DAI J，ZHOU X，DONG D，et al. Human infection with a novel avian-origin influenza A （H7N9） virus：serial chest radiographic and CT findings[J] . Chin Med J，2014，127（12）：2206-2211. [26] KO S F，LEE T Y，HUANG C C，et al. Severe acute respiratory syndrome：prognostic implications of chest radiographic findings in 52 patients[J] . Radiology，2004，233（1）：173-181. [27] SIMONSEN L，TAYLOR R J，YOUNG-XU Y，et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States[J] . mBio，2011，2（1）：e00309-e00310. [28] 陈炜，陈金强，鲁君敏，等. 3例人感染H7N9禽流感重症病例临床特征分析[J] . 预防医学，2016，28（10）：1031-1033. [29] GOKA E A，VALLELY P J，MUTTON K J，et al. Mutations associated with severity of the pandemic influenza A（H1N1）pdm09 in humans：a systematic review and meta-analysis of epidemiological evidence[J] . Arch Virol，2014，159（12）：3167-3183. [30] WANG C B，CHIU M L，LIN P C，et al. Prompt oseltamivir therapy reduces medical care and mortality for patients with influenza infection：An Asian population cohort study[J] . Medicine （Baltimore），2015，94（27）：e1070. [31] ADISASMITO W，CHAN P K，LEE N，et al. Effectiveness of antiviral treatment in human influenza A（H5N1） infections：analysis of a Global Patient Registry[J] . J Infect Dis，2010，202（8）：1154-1160. [32] YANG S，CAO B，LIANG L，et al. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic （H1N1） virus [J] . Plos one，2012，7（1）：e29652.
